Quality of life following bone marrow transplantation: a comparison of patient reports with population norms

Sutherland, Heather J.; Fyles, Gillian; Adams, Grenfell; Hao, Yong; Lipton, Jeffrey H.; Minden, Mark D.; Meharchand, J.; Atkins, Harry; Tejpar, I; Messner, Hans A.

doi:10.1038/sj.bmt.1700806

Cited by 142 publications

(114 citation statements)

References 2 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…In bold, significant difference with norm group. In italics, significant difference between pre-and post-SCT PSI parenting stress index *p≤0.05 average 10 months post-SCT, which is still a more or less active treatment period, whereas other researchers reported improved HRQoL [19] using an interval of 3 years [40] or 5 years posttransplantation [11]. It is possible that our follow-up period post-SCT was too short to detect any time effects and needs to be extended in further studies.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Child and parental adaptation to pediatric stem cell transplantation

Vrijmoet-Wiersma

Kolk

Grootenhuis

et al. 2008

Support Care Cancer

View full text Add to dashboard Cite

Goals of work Allogeneic pediatric stem cell transplantation (SCT) is a very intensive treatment with a high mortality and morbidity. The objectives of this study were to assess the (1) self-and proxy-reported health-related quality of life (HRQoL) compared to a norm group, (2) levels of parenting stress compared to a norm group, (3) differences in HRQoL and parenting stress pre-and post-SCT, and (4) effect of child age and parenting stress on selfand proxy-reported HRQoL pre-and post-SCT. Materials and methods Pre-and on average 10 months post-SCT, 21 children and adolescents and their parent(s) completed questionnaires on HRQoL and the mothers completed a measure of parenting stress. Main results Post-SCT, home functioning, physical functioning, and total HRQoL scores were lower than the norm group. We found stable HRQoL scores over time with the exception of the domain home functioning, which was rated lower post-SCT than pre-SCT. Parents reported lower HRQoL scores than the children pre-and post-SCT and younger children experienced better HRQoL than older children. Parenting stress was higher post-SCT than pre-SCT and high levels of parenting stress were predictive of poor parental ratings of child HRQoL post-SCT. Conclusions Ongoing psychosocial assessment post-SCT is necessary to target children with a lowered HRQoL and parents who experience elevated parenting stress who may be in greater need of more supportive care.

show abstract

Section: Discussionmentioning

confidence: 94%

“…Most HRQoL research in SCT patients has been conducted with adults. In the majority of the studies, a negative impact on the HRQoL evaluation in a proportion of adults has been found [9,11,40], often due to functional limitations and somatic symptoms [9] and to concerns about relapsing [2,4].…”

mentioning

confidence: 99%

Child and parental adaptation to pediatric stem cell transplantation

Vrijmoet-Wiersma

Kolk

Grootenhuis

et al. 2008

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Thus many patients with chronic GVHD receive systemic IST for an extended period, which is associated with a high risk for morbidity such as renal failure, hyperglycaemia, hypertension, avascular necrosis, osteoporosis and infections. Chronic GVHD has been reported to be associated with poor patient QOL after HCT (Sutherland et al, 1997;Chiodi et al, 2000;Kiss et al, 2002) and the duration of systemic IST may contribute to a poor QOL. However, less attention has been given to the duration of systemic IST in patients with chronic GVHD.…”

Section: Discussionmentioning

confidence: 99%

“…Infection is the most common cause of death in patients with chronic GVHD (Storb et al, 1983;Sullivan et al, 1988a;Kulkarni et al, 2000). Chronic GVHD may also compromise a patient's quality of life (QOL) due to chronic immunosuppressive therapy (IST) and the symptoms of GVHD itself (Sutherland et al, 1997;Chiodi et al, 2000;Kiss et al, 2002). Chronic GVHD appears to be one of the major determinants in the survival and QOL of patients after allogeneic HCT.…”

mentioning

confidence: 99%

Graft‐versus‐host disease (GVHD)‐specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation

Lee

Choi

et al. 2003

Br J Haematol

View full text Add to dashboard Cite

Summary. We investigated graft-versus-host disease (GVHD)-specific survival (GSS) and the duration of systemic immunosuppressive treatment (IST) in 82 patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation (HCT). These two major study endpoints were calculated using the Kaplan-Meier method. Deaths solely due to the relapse of underlying disease or accidental deaths were censored at the time of occurrence for the analysis of GSS. The probability of GSS at 5 years was 74AE2%. The median duration of systemic IST for chronic GVHD was 272 d (range: 7-1450), and the probability of withdrawal of systemic IST at 1, 2 and 3 years was 67AE3%, 82AE4% and 89AE0% respectively. Analysis based on a multivariate model showed that a diagnosis other than leukaemia or myelodysplastic syndrome (P ¼ 0AE049), prior occurrence of grade III-IV acute GVHD (P ¼ 0AE021), onset of chronic GVHD before d 120 (P ¼ 0AE013), serum alkaline phosphatase over 120 IU/l (P ¼ 0AE034), and serum bilirubin over 34AE2 lmol/l (P ¼ 0AE015) were independent adverse prognostic factors for GSS. Prior occurrence of grade III-IV acute GVHD significantly influenced the duration of systemic IST (P ¼ 0AE048). In conclusion, analyses of GSS and the duration of systemic IST will allow patients with different outcomes to be stratified for appropriate treatment application and will provide important parameters in prospective trials for the treatment of chronic GVHD.

show abstract

“…On the other hand, several studies demonstrate that HRQOL returns to normal within 3-5 years after HSCT, whereas mental health can recover to desirable levels. [22][23][24][25] Some authors suggest that patients faced with the procedure and complications of HSCT pay more attention to and spare more effort toward cultivating their psychosocial domain; a positive attitude is also necessary for a patient to be a long-term survivor. 22 Furthermore, an increased feeling of well-being may reflect a sense of personal triumph at overcoming the odds, which could accompany posttransplant survival.…”

Section: Discussionmentioning

confidence: 99%

Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

Jiang

et al. 2014

Bone Marrow Transplant

View full text Add to dashboard Cite

To evaluate and compare the health-related quality of life (HRQOL) of patients with newly diagnosed CML in the first chronic phase (CML-CP1) receiving HLA-identical sibling donor (ISD) hematopoietic SCT (HSCT) or imatinib, a cross-sectional study that was part of a prospective cohort study at the Institute of Hematology, Peking University was performed. A total of 222 patients including 126 and 96 in the imatinib and ISD HSCT groups, respectively, were enrolled. HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey. The ISD HSCT group functioned significantly better on the role-physical functioning and mental health subscales, as well as the mental component summary (MCS) than the imatinib group. HRQOL was generally comparable to groups in the young population. Multivariate analysis showed that white blood cell countX30 Â 10 9 /L and plts count X450 Â 10 9 /L were the major adverse factors affecting HRQOL in long-term survivors. Imatinib therapy was also an adverse factor affecting the MCS (odds ratio ¼ 1.7, P ¼ 0.032). Thus, long-term CML-CP1 survivors receiving ISD HSCT can attain desirable HRQOL comparable to or better than that of patients receiving imatinib.

show abstract

Quality of life following bone marrow transplantation: a comparison of patient reports with population norms

Abstract: Summary:Health-related quality of life data can be used at the micro, meso and macro levels of decision making.

Cited by 142 publications

References 2 publications

Child and parental adaptation to pediatric stem cell transplantation

Child and parental adaptation to pediatric stem cell transplantation

Graft‐versus‐host disease (GVHD)‐specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation

Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib

Contact Info

Product

Resources

About